DasarahallySMohanMD(He/Him)
Radiation Oncology • South San Francisco, CARadiation Oncologist, The Permanente Medical Group-NCaL
Dr. Mohan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1200 El Camino Real
South San Francisco, CA 94080Phone+1 650-827-6500Fax+1 510-625-6226
Summary
- Dr. Dasarahally Mohan is a Radiation Oncologist based in South San Francisco, specializing in prostate cancer, Breast Cancer and Gynecologic Cancer treatment. He completed his medical education at Bangalore Medical College and further training at Brooklyn Hospital Center, Case Western Reserve University, and Cleveland Clinic Foundation. Since 2003, he has been with the KP Cancer Treatment Center. Dr. Mohan's research has focused on improving patient-reported outcomes and reducing toxicity in radiation therapy. His work has been published in reputable journals, with notable citations. He has participated in clinical trials, including studies on prostate cancer and breast cancer. In 2011, he received the Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services.
Education & Training
Cleveland Clinic FoundationResidency, Radiation Oncology, 1996 - 2000
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Radiation Oncology, 1996 - 1997
Brooklyn Hospital CenterInternship, Internal Medicine, 1995 - 1996
Bangalore Medical CollegeClass of 1986
Certifications & Licensure
CA State Medical License 2003 - 2026
UT State Medical License 2003 - 2006
OH State Medical License 2000 - 2000
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Start of enrollment: 2021 Nov 03
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Start of enrollment: 2020 Dec 15
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer Start of enrollment: 2018 Oct 16
Publications & Presentations
PubMed
- Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.Andre Konski, Snehal Deshmukh, Ann H Klopp, Anamaria R Yeung, Shannon N Westin
Gynecologic Oncology. 2023-08-01 - 14 citationsIntensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial.Anamaria R Yeung, Snehal Deshmukh, Ann H Klopp, Karen M Gil, Lari Wenzel
Journal of Clinical Oncology. 2022-09-20 - 75 citationsImprovement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 StudyAnamaria R. Yeung, Stephanie L. Pugh, Ann H. Klopp, Karen M. Gil, Lari Wenzel
Journal of Clinical Oncology. 2020-02-19
Professional Memberships
- ASTROMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
